Hereditary transthyretin amyloidosis overview.
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D.
Neurol Sci. 2022 Dec;43(Suppl 2):595-604. doi: 10.1007/s10072-020-04889-2. Epub 2020 Nov 14.
Polyneuropathies.
Sommer C, Geber C, Young P, Forst R, Birklein F, Schoser B.
Dtsch Arztebl Int. 2018 Feb 9;115(6):83-90. doi: 10.3238/arztebl.2018.083.
Polyglutamine androgen receptor-mediated neuromuscular disease.
Giorgetti E, Lieberman AP.
Cell Mol Life Sci. 2016 Nov;73(21):3991-9. doi: 10.1007/s00018-016-2275-1. Epub 2016 May 17.
Toxic Neuropathies.
McNeish BL, Kolb N.
Continuum (Minneap Minn). 2023 Oct 1;29(5):1444-1468. doi: 10.1212/CON.0000000000001343.
Toxic neuropathies.
Rossor AM, Manji H.
Curr Opin Neurol. 2023 Oct 1;36(5):402-409. doi: 10.1097/WCO.0000000000001193. Epub 2023 Aug 2.
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G, Antonini G, Garibaldi M.
Autoimmun Rev. 2022 Feb;21(2):102993. doi: 10.1016/j.autrev.2021.102993. Epub 2021 Nov 16.
Toxic myopathies.
Pasnoor M, Barohn RJ, Dimachkie MM.
Curr Opin Neurol. 2018 Oct;31(5):575-582. doi: 10.1097/WCO.0000000000000606.
Toxic RNA in the nucleus: unstable microsatellite expression in neuromuscular disease.
Nykamp KR, Swanson MS.
Prog Mol Subcell Biol. 2004;35:57-77. doi: 10.1007/978-3-540-74266-1_3.
Other Myopathies.
Hussain Y, Miller S.
Neurol Clin. 2020 Aug;38(3):619-635. doi: 10.1016/j.ncl.2020.04.002.
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS.
Molecules. 2017 Apr 5;22(4):563. doi: 10.3390/molecules22040563.
